A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

Clinical trial NCT02531698 · COMPLETED

Trial details

NCT number: NCT02531698
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

MENINGOCOCCAL INFECTION

Start date: 2015-08-01
Primary completion: 2017-03-01
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.